Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., and TetraGenetics, Inc., a biotech company developing novel therapeutics for pain indications and autoimmune diseases, today announced a strategic research & development collaboration to utilize TetraGenetics’ antibody discovery technology platform (TetraExpress™) in the discovery and development of non-opioid biologic therapies for the treatment of chronic pain.

Imbrium will leverage TetraGenetics’ proprietary TetraExpress™ system to advance monoclonal antibodies that target specific ion channels that are scientifically important in the modulation of pain sensation. The goal of this collaborative effort is to bring to market long-acting, non-opioid therapeutics that can treat a variety of pain conditions.

"We are encouraged by the potential of TetraGenetics’ technology platform to speed the development of transformative therapies that could have a positive impact in the management of chronic pain," said Paul Medeiros, president, Imbrium Therapeutics. "Given the high prevalence of chronic pain in the US,1 we are excited about progressing our partnership with the goal of bringing forward new, safe, and effective treatment alternatives. This opportunity underscores our mission to provide non-opioid pain medicines for patients in need."

"Ion channel antibody discovery holds great promise for the treatment of chronic pain, and we are pleased to have the resources and support of Imbrium to advance this important program," said Doug Kahn, chairman and CEO, TetraGenetics. "During the course of our collaboration, we expect to bring new antibody therapeutics to investigational new drug application (IND) readiness so Imbrium can advance them through clinical trials. We look forward to working with Imbrium to develop and bring to the medical community new, non-opioid therapeutic options for patients living with chronic pain."

"Patients suffering from chronic pain need more non-opioid treatment options," said Craig Landau, MD, president and CEO, Purdue Pharma L.P. "This collaboration is another example of our commitment to address the evolving needs of those patients and their healthcare providers through the research & development of non-opioid solutions. It demonstrates our commitment, through Purdue’s subsidiary Imbrium, to building a pipeline through internal research, strategic collaborations and partnerships."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.